Digital Therapeutics Alliance

What Digital Therapeutics Alliance does

The Digital Therapeutics Alliance (DTA) is a 501(c)(6) non-profit trade association founded in 2017 and headquartered in Arlington, Virginia. It is the leading international organization on digital therapeutics (DTx) thought leadership, education, and policy advocacy, convening more than 60 member organizations across 17 countries and five continents — including DTx manufacturers, pharmaceutical companies (notably Akili Interactive, HelloBetter, Welldoc, Propeller Health, Freespira, MedRhythms), clinicians, payors, policymakers, and investors. Its mission is to broaden the understanding, adoption, and integration of clinically evaluated digital therapeutics into healthcare to improve clinical and health economic outcomes.

DTA's core offerings are educational resources, industry frameworks, and policy assets rather than software products. These include the foundational DTx Definition and Core Principles (2018), the DTx Value Assessment & Integration Guide (the first industry framework for evaluating DTx), the Policymaker & Payor DTx Evaluation Toolkit, the DTx Product Library (a curated directory of member products such as Dario, Daylight, EndeavorOTC, Sleepio meeting ISO DTx standards), the DTx Accreditation Program (administered with DirectTrust), and the first DTx Continuing Medical Education module (with the Post Graduate Institute for Medicine). DTA also convenes task groups and advisory boards (Clinician Advisory Group, Payor Accelerator Board, Investor Advisory Board) and engages regulators (FDA, CMS) and international policy bodies on reimbursement frameworks.

DTA generates revenue primarily through tiered annual membership dues ($750 for pre-revenue companies up to $25,000 for members with $75M+ revenue), regional add-on memberships for APAC and Europe, and event revenue from the Nexus conference (formerly the DTA Summit, merged with ATA's Nexus in 2025). In April/May 2025, DTA was acquired by ATA Action, the policy and lobbying arm of the American Telemedicine Association, to create a unified digital health advocacy platform.

Name

Digital Therapeutics Alliance

Legal name

Digital Therapeutics Alliance, Inc.

Website

https://dtxalliance.org

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

DTA is a global non-profit trade association that advances evidence-based digital therapeutics through standardized evaluation frameworks, policy advocacy, and convening 60+ member organizations across 17 countries in the DTx industry.

Ownership category

akta.pro rank

Product category

Digital Health Industry Trade Association / DTx Advocacy and Education

NAICS

Professional Organizations (81392)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Condition-specific Digital Therapeutics (DTx) (HLACANAA)

akta.pro secondary industries

DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM), Behavioral Health Digital Therapeutics (DTx) & Virtual Care Partner Management (HLAEAHAJ)

Keywords

• Digital therapeutics advocacy
• Healthcare policy education
• Industry trade association
• DTx evaluation frameworks
• Medical education programs

Headquarters

HQ city

Arlington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership Dues: DTA generates revenue primarily through membership dues paid by member organizations. Membership dues are tiered based on the member company's annual global revenue, ranging from $750 for pre-revenue companies up to $25,000 for companies with $75 million+ revenue.
2. APAC Membership: DTA offers Asia-Pacific specific membership with tiered annual dues based on global revenue of member organizations. Includes participation in APAC Task Group meetings, Slack and WeChat channels, member events, and newsletters.
3. European Membership: DTA offers European-specific membership with access to bimonthly Europe Policy Task Group meetings, Europe Slack channel, member events, and bimonthly newsletters. Revenue generated through tiered annual dues.
4. Event Sponsorships and Registration: Revenue generated through event registrations and sponsorships for annual DTA Summits and the Nexus conference. DTA members receive exclusive registration pricing ($1,200 for Nexus 2025).

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

Core offering

The Digital Therapeutics Alliance is a non-profit trade association that advances evidence-driven digital therapeutics through industry advocacy, education, and cross-stakeholder collaboration. It sells tiered membership programs (general, APAC, European) to DTx companies and related organizations, and offers industry frameworks and resources including the DTx Evaluation Toolkit, DTx Value Assessment & Integration Guide, DTx Product Library, DTx Accreditation Program (with DirectTrust), and a foundational DTx CME course, alongside the annual Nexus conference.

Product overview

The Digital Therapeutics Alliance is an industry trade association (501(c)(6)), not a product company. It does not manufacture digital therapeutic products. Its offerings consist of industry services including: DTx Continuing Medical Education (CME) - a foundational course for healthcare professionals on digital therapeutics; the DTx Evaluation Toolkit - providing frameworks for product evaluation and implementation; DTx Accreditation Program - in partnership with DirectTrust for efficacy and data privacy/security certification; the DTx Value Assessment & Integration Guide - an industry framework for evaluating digital therapeutics; the DTx Product Library - a directory of member company products meeting DTx standards; and the Nexus annual conference. The DTA Product Library lists member company products (such as Dario, Daylight, EndeavorOTC, Freespira, HelloBetter, Propeller, Sleepio, Welldoc) but these are not DTA products. The sole DTA-developed educational product is the DTx CME.

Differentiator

Problem solved

Functional benefit

Products and services

• DTx Continuing Medical Education (CME) A foundational continuing medical education course that educates healthcare professionals about digital therapeutics, covering the ISO definition of DTx, differentiation of healthcare professional and patient-facing digital health technologies, criteria for DTx categorization, and patient populations impacted by DTx access. Available through CME University and developed in partnership with the Post Graduate Institute for Medicine.
• Policymaker & Payor DTx Evaluation Toolkit A comprehensive toolkit providing a common language and process for Healthcare Decision Makers (HCDMs) and DTx manufacturers to jointly use throughout DTx product evaluation and implementation processes. Addresses HCDM considerations across health systems, employers, private payors, and single-payor government systems.
• DTx Accreditation Program An accreditation program administered by DirectTrust in partnership with DTA that provides accreditation for efficacy, data privacy, and security for digital therapeutic products. Builds upon DirectTrust's established Privacy and Security accreditation program by adding a layer for product efficacy.
• DTx Value Assessment & Integration Guide An industry framework to streamline the process of evaluating and bringing safe and effective digital therapeutics into clinical use. Provides resources for assessing clinical impact, regulatory requirements, clinical evidence, economic assessment, and implementation in practice for payors, clinicians, and manufacturers.
• DTx Product Library A public repository of evidence-based, innovative DTx products from member companies that are currently on the market, meet the ISO definition of a DTx product, and attest to aligning with industry Core Principles. Includes member products such as Dario Platform, Daylight, EndeavorOTC, Freespira, HelloBetter products, Propeller, Sleepio, and Welldoc App.
• Nexus Annual Conference The premier industry event for advancing digital health and care delivery, held May 3-6, 2025 in New Orleans, LA. Brings together experts, clinicians, C-suite leaders, researchers, and investors to foster collaboration, explore innovation, and provide tools to drive meaningful change in DTx adoption. DTA members receive exclusive registration at $1,200.
• General Membership Program Tiered annual membership for DTx companies, healthcare systems, pharmaceutical manufacturers, academic institutions, and other stakeholders. Includes engagement forums, roundtable discussions, work groups, access to industry frameworks, and regional membership meetings. Annual dues range from $750 to $25,000 based on member company revenue.
• APAC Membership Asia-Pacific specific membership tier with access to monthly APAC Task Group meetings, APAC Slack and WeChat channels, member events, and monthly newsletters. Tiered annual dues based on member organization's global revenue.
• European Membership European-specific membership tier with access to bimonthly Europe Policy Task Group meetings, Europe Slack channel, member events, and bimonthly newsletters. Tiered annual dues based on member organization's global revenue.

Quantifiable outcome

• Global DTx market projected to grow from USD 6.84 billion in 2024 to USD 39.52 billion by 2033 (21.6% CAGR)
• +3 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• ATA ActioncoreStrategic or Co-development Partner · 1 May 2025ATA Action, the advocacy arm of the American Telemedicine Association, acquired the Digital Therapeutics Alliance in May 2025 to create a unified policy and advocacy platform for digital therapeutics in the U.S. healthcare system. The acquisition aimed to strengthen digital therapeutics policy efforts and increase the organization's international and state-level influence.
• MedliveminorStrategic or Co-development Partner · 1 February 2025DTA collaborated with Medlive on a joint survey to provide strategic insights for DTx companies on engaging with patient advocacy groups. Results were shared in a publication and webinar.
• PlatformQ HealthminorStrategic or Co-development Partner · 1 February 2025DTA partnered with PlatformQ Health for a joint survey on patient advocacy group engagement. Based on survey results, a webinar was hosted providing insights on how DTx companies can effectively collaborate with patient advocacy groups.
• Post Graduate Institute for Medicine (PIM)coreStrategic or Co-development Partner · 1 August 2024DTA partnered with the Post Graduate Institute for Medicine (PIM) to launch the first continuing medical education (CME) module for digital therapeutics, titled 'Understanding the Future of Digital Therapeutics'. This foundational CME course educates healthcare professionals about the DTx field.
• DirectTrustcoreStrategic or Co-development Partner · 6 June 2024DTA partnered with DirectTrust to establish an accreditation program specific to digital therapeutic products. The program builds upon DirectTrust's established Privacy and Security accreditation program by adding a layer for product efficacy. The DTx Criteria Council published the first draft of DTx Accreditation Criteria in September 2024, with a 60-day public comment period ending November 22, 2024.
• Healthware GroupcoreStrategic or Co-development Partner · 1 January 2023DTA partnered with Healthware Group to publish the DTx Policy Pathways report - a landscape analysis of digital medical devices in Europe aimed at establishing enabling policies for digital medical devices and DTx to drive equitable access to digital healthcare.
• NCPDP (National Council for Prescription Drug Programs)coreStrategic or Co-development Partner · 1 January 2023DTA collaborated with NCPDP to publish the DTx Integration and Workflow Report series (2023, March 2024, September 2024), outlining the integration and workflow of DTx products in the U.S. healthcare system using the patient journey as the focal point.
• CurebaseminorStrategic or Co-development Partner · 1 December 2022DTA partnered with Curebase to publish 'Setting the Stage for a Fit-For-Purpose DTx Evidentiary Standard', providing a foundational set of expectations outlining necessary clinical evidence for efficient and appropriate DTx product assessment.
• ClearView Healthcare PartnersminorStrategic or Co-development Partner · 1 January 2022DTA collaborated with ClearView Healthcare Partners to develop the DTx Commercial Launch Playbook for DTA members. The playbook provides a standard set of launch considerations for successful product launches and scaling. A case study with Freespira was also published.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• American Telemedicine Association (ATA): ATA is now the parent of ATA Action, which acquired DTA in 2025. ATA is the broader US trade association for telehealth and virtual care, and serves overlapping stakeholders (clinicians, policymakers, payors) and convenes the Nexus conference that absorbed DTA's annual summit.
• HIMSS (Healthcare Information and Management Systems Society): HIMSS is a large global health information and technology trade association serving clinicians, payors, and policymakers. Like DTA, it develops education, policy positions, and large annual conferences (HIMSS Global Conference), making it a comparable membership-based health IT advocacy organization.
• AdvaMed (Advanced Medical Technology Association): AdvaMed is the leading US trade association for medical technology and device companies. It provides policy advocacy, industry frameworks, and member education—overlapping DTA's mission of shaping reimbursement and regulatory pathways for technology-enabled medical products.
• BIO (Biotechnology Innovation Organization): BIO is the world's largest biotechnology trade association, representing therapeutic developers and advocating for regulatory and reimbursement reforms. Its policy advocacy, member education, and conference (BIO International Convention) model closely parallels DTA's role in the DTx category.
• Consumer Technology Association (CTA): CTA operates CES and a Digital Health track that covers connected health, wearables, and digital therapeutics-adjacent products. It is a comparable industry trade body convening consumer digital health stakeholders through events and standards work.

Direct peers

• CHIME (College of Healthcare Information Management Executives): CHIME is a US-based professional membership organization for healthcare IT leaders, focused on education, advocacy, and policy influence. It mirrors DTA's community-led model of convening specialized healthcare stakeholders and producing frameworks/education resources.
• American Medical Informatics Association (AMIA): AMIA is a professional association for informatics professionals in healthcare, advancing policy, education, and applied research. It overlaps DTA in the digital health education and policy advocacy space and convenes specialized clinical/technical communities.
• Digital Medicine Society (DiMe): DiMe is a non-profit professional society focused on digital health and digital medicine, building evidence-based playbooks, education, and community resources. It is a close peer to DTA in mission, structure, and target stakeholder base, though with a broader digital medicine rather than DTx-only focus.
• Personal Connected Health Alliance (PCHA): PCHA advances consumer-centric connected health technologies through standards (Continua), policy advocacy, and events. It operates as an analogous membership organization shaping technology-enabled health adoption globally.

Regional players

• Medical Device Manufacturers Association (MDMA): MDMA is a US national trade association representing innovative medical device companies, with a parallel focus on reimbursement, regulatory, and commercialization policy advocacy—mirroring DTA's efforts on the SaMD/DTx subsegment of the medical device industry.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/dtx_alliance

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Digital Therapeutics Alliance